Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiol TherapeuticsSTU:CT9 +2.61%27 Equity-to-Asset is 0.82 as of Jun. 2026, which is 4% below its 10-year median of 0.85. GuruFocus rates STU:CT9 with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Cardiol Therapeutics ranks better than 83.42% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Cardiol Therapeutics Equity-to-Asset Related Terms
Cardiol Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Cardiol Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cardiol Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiol Therapeutics Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cardiol Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Cardiol Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Cardiol Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiol Therapeutics (STU:CT9) has a Equity-to-Asset of 0.82 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cardiol Therapeutics and its competitors. This is near median its historical median of 0.85. According to the industry distribution chart, Cardiol Therapeutics ranks #167 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 16.6%.
Is Cardiol Therapeutics' Equity-to-Asset too high?
Cardiol Therapeutics' current Equity-to-Asset of 0.82 is near median its 10-year median of 0.85. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Cardiol Therapeutics' value of 0.82 is 36.7% above this industry median. Based on the distribution chart, Cardiol Therapeutics ranks #167 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cardiol Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Cardiol Therapeutics' Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cardiol Therapeutics ranks #167 out of 1007 companies for Equity-to-Asset. This places Cardiol Therapeutics in the top 17% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.60. Cardiol Therapeutics' value of 0.82 is 36.7% above this benchmark. While the company's 10-year median is 0.85 vs. the industry median of 0.60, Cardiol Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardiol Therapeutics's current Equity-to-Asset of 0.82 is 36.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cardiol Therapeutics and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiol Therapeutics's current Equity-to-Asset is 0.82, which is near median its own 10-year median of 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiol Therapeutics stock overvalued right now?
Cardiol Therapeutics (STU:CT9) has a current Equity-to-Asset of 0.82. The current Equity-to-Asset is 0.82, which is near median its 10-year median of 0.85 and 36.7% above the Drug Manufacturers industry median of 0.60. Cardiol Therapeutics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Cardiol Therapeutics (STU:CT9), the current Equity-to-Asset is 0.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
27GF Score
Get the complete analysis for STU:CT9
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CT9 has been successfully added to your 
